The state of Texas currently has 185 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Recruiting
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Saint Joseph Regional Cancer Center, Bryan, Texas +3 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Recruiting
To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Recruiting
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to esta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Texas Oncology - Amarillo, Amarillo, Texas +10 locations
Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Recruiting
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib In Non-United States (US) Participants Only: Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Ri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: The University of Texas Southwestern Medical Centre, Dallas, Texas +1 locations
Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-naïve High Risk Chronic Lymphocytic Leukemia, Richter's Syndrome
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Recruiting
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study. This study is made up of 3 parts: Part 1A (non-randomiz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Center for Oncology and Blood Disorders, Houston, Texas
Conditions: Follicular Lymphoma (FL)
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Recruiting
This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Burkitt-Like Lymphoma With 11q Aberration, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Recruiting
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More
Gender:
ALL
Ages:
Between 5 years and 60 years
Trial Updated:
07/29/2025
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas +13 locations
Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruiting
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Recruiting
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: * Pretreatment, which consists of screening assessme... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Texas Oncology, Dallas, Texas +2 locations
Conditions: Lymphoma, Non-Hodgkin
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
Recruiting
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Recruiting
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body). The study has three parts: * Part A will test PF-08046032 alone at increasing dose levels in participants with certain lymp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Recruiting
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: MD Anderson, Houston, Texas +1 locations
Conditions: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma